MITRACLIP DELIVERY SYSTEM

Mitral Valve Repair Devices

FDA Premarket Approval P100009

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the mitraclip clip delivery system (mitraclip cds). This device is indicated for the percutaneous reduction ofsignificant symptomatic mitral regurgitation (mr >= 3+) due to primary abnormality of the mitral apparatus [degenerative mr] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.

DeviceMITRACLIP DELIVERY SYSTEM
Classification NameMitral Valve Repair Devices
Generic NameMitral Valve Repair Devices
ApplicantABBOTT VASCULAR INC.
Date Received2010-03-04
Decision Date2013-10-24
Notice Date2013-11-15
PMAP100009
SupplementS
Product CodeNKM
Docket Number13M-1365
Advisory CommitteeCardiovascular
Expedited ReviewYes
Combination Product No
Applicant Address ABBOTT VASCULAR INC. 3200 Lakeside Drive santa Clara, CA 95054
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P100009Original Filing
S051 2023-01-03 30-day Notice
S050 2022-11-16 30-day Notice
S049 2022-11-09 30-day Notice
S048 2022-10-11 30-day Notice
S047 2022-08-25 30-day Notice
S046 2022-07-22 30-day Notice
S045 2022-01-31 Normal 180 Day Track No User Fee
S044 2021-09-22 30-day Notice
S043 2021-07-26 30-day Notice
S042 2021-03-31 Real-time Process
S041
S040
S039 2021-02-08 30-day Notice
S038 2021-01-25 30-day Notice
S037 2020-01-31 30-day Notice
S036 2019-09-03 30-day Notice
S035 2019-08-19 30-day Notice
S034 2019-08-06 Special (immediate Track)
S033 2019-06-28 Special (immediate Track)
S032 2019-06-24 30-day Notice
S031
S030 2019-05-03 Special (immediate Track)
S029
S028 2018-11-06 Panel Track
S027 2018-05-31 135 Review Track For 30-day Notice
S026 2018-05-15 Normal 180 Day Track No User Fee
S025 2017-10-24 Normal 180 Day Track
S024 2017-05-26 30-day Notice
S023 2017-04-03 30-day Notice
S022 2017-03-29 30-day Notice
S021 2016-06-15 135 Review Track For 30-day Notice
S020 2016-06-06 30-day Notice
S019 2016-05-26 30-day Notice
S018 2016-05-11 Real-time Process
S017 2016-03-01 Special (immediate Track)
S016 2015-11-18 Normal 180 Day Track No User Fee
S015 2015-10-01 Normal 180 Day Track
S014 2015-09-30 30-day Notice
S013 2015-09-15 30-day Notice
S012 2015-05-04 Real-time Process
S011 2015-04-08 30-day Notice
S010 2015-03-30 Normal 180 Day Track No User Fee
S009 2014-11-24 30-day Notice
S008 2014-11-19 30-day Notice
S007 2014-07-11 30-day Notice
S006 2014-06-16 30-day Notice
S005 2014-05-01 Special (immediate Track)
S004 2014-04-18 Real-time Process
S003
S002 2013-11-26 Normal 180 Day Track No User Fee
S001 2013-11-26 Normal 180 Day Track No User Fee

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.